Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

MLA

Insa, Amelia, et al. “Which Treatment after First Line Therapy in NSCLC Patients without Genetic Alterations in the Era of Immunotherapy?” Critical Reviews in Oncology/Hematology, vol. 169, Jan. 2022, p. 103538. EBSCOhost, https://doi.org/10.1016/j.critrevonc.2021.103538.

APA

Insa, A., Martín-Martorell, P., Di Liello, R., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., & Della Corte, C. M. (2022). Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? Critical Reviews in Oncology/Hematology, 169, 103538. https://doi.org/10.1016/j.critrevonc.2021.103538

Chicago

Insa, Amelia, Paloma Martín-Martorell, Raimondo Di Liello, Morena Fasano, Giulia Martini, Stefania Napolitano, Giovanni Vicidomini, et al. 2022. “Which Treatment after First Line Therapy in NSCLC Patients without Genetic Alterations in the Era of Immunotherapy?” Critical Reviews in Oncology/Hematology 169 (January): 103538. doi:10.1016/j.critrevonc.2021.103538.